Dermatologists give views on impact of Eli Lilly's Taltz and Novartis' Cosentyx

20 September 2016

Taltz (ixekizumab), a monoclonal antibody (MOA) from US pharma major Eli Lilly (NYSE: LLY), and Swiss pharma giant Novartis’ (NOVN: VX) Cosentyx (secukinumab), will make gains in the psoriasis market at the cost of sales of TNF-inhibitors, predicts a report based on a survey of 99 US dermatologists.

The report from Spherix Global Insights shows that more than 70% of the dermatologists say that their biologic use has increased over the past year, playing catch up with rheumatologists' use in psoriatic arthritis.

They are also shifting their mix of various MOAs, with most agreeing with the statement: “I anticipate decreasing my use of TNF-inhibitors and increasing my use of alternative MOAs for the treatment of psoriasis in the near future."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK